A landscape of synthetic viable interactions in cancer

&NA; Synthetic viability, which is defined as the combination of gene alterations that can rescue the lethal effects of a single gene alteration, may represent a mechanism by which cancer cells resist targeted drugs. Approaches to detect synthetic viable (SV) interactions in cancer genome to investigate drug resistance are still scarce. Here, we present a computational method to detect synthetic viability‐induced drug resistance (SVDR) by integrating the multidimensional data sets, including copy number alteration, whole‐exome mutation, expression profile and clinical data. SVDR comprehensively characterized the landscape of SV interactions across 8580 tumors in 32 cancer types by integrating The Cancer Genome Atlas data, small hairpin RNA‐based functional experimental data and yeast genetic interaction data. We revealed that the SV interactions are favorable to cells and can predict clinical prognosis for cancer patients, which were robustly observed in an independent data set. By integrating the cancer pharmacogenomics data sets from Cancer Cell Line Encyclopedia (CCLE) and Broad Cancer Therapeutics Response Portal, we have demonstrated that SVDR enables drug resistance prediction and exhibits high reliability between two databases. To our knowledge, SVDR is the first genome‐scale data‐driven approach for the identification of SV interactions related to drug resistance in cancer cells. This data‐driven approach lays the foundation for identifying the genomic markers to predict drug resistance and successfully infers the potential drug combination for anti‐cancer therapy.

[1]  Ben Lehner,et al.  Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types , 2015, Molecular systems biology.

[2]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[3]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[4]  Min Zhang,et al.  Systematic Interpretation of Comutated Genes in Large-Scale Cancer Mutation Profiles , 2010, Molecular Cancer Therapeutics.

[5]  F. Vizeacoumar,et al.  Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell. , 2014, Trends in molecular medicine.

[6]  Erik L. L. Sonnhammer,et al.  InParanoid 7: new algorithms and tools for eukaryotic orthology analysis , 2009, Nucleic Acids Res..

[7]  Trey Ideker,et al.  A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy. , 2016, Molecular cell.

[8]  Gary D. Bader,et al.  Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..

[9]  Shridar Ganesan,et al.  Loss of 53 BP 1 causes PARP inhibitor resistance in BRCA 1-mutated mouse mammary tumors , 2012 .

[10]  Francesco Iorio,et al.  Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery. , 2014, Pharmacogenomics.

[11]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[12]  Scott E. Martin,et al.  Reproducible pharmacogenomic profiling of cancer cell line panels , 2016, Nature.

[13]  J. Inazawa,et al.  Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. , 2001, Cancer research.

[14]  Keiko Akagi,et al.  Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies , 2016, Nature Communications.

[15]  David E. Housman,et al.  Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines , 2013, PloS one.

[16]  Benjamin Haibe-Kains,et al.  Inconsistency in large pharmacogenomic studies , 2013, Nature.

[17]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[18]  Alan F. Rubin,et al.  Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers" , 2007, Science.

[19]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[20]  Michael L. Creech,et al.  Integration of biological networks and gene expression data using Cytoscape , 2007, Nature Protocols.

[21]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[22]  Hui Liu,et al.  SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets , 2015, Nucleic Acids Res..

[23]  D. Kell,et al.  The Kyoto Encyclopedia of Genes and Genomes—KEGG , 2000, Yeast.

[24]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[25]  Shridar Ganesan,et al.  BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. , 2011, Journal of molecular cell biology.

[26]  Jeff Piotrowski,et al.  A comparative genomic approach for identifying synthetic lethal interactions in human cancer. , 2013, Cancer research.

[27]  Wei Chen,et al.  Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors. , 2015, ACS medicinal chemistry letters.

[28]  Peter Bouwman,et al.  REV7 counteracts DNA double-strand break resection and affects PARP inhibition , 2015, Nature.

[29]  W. Hahn,et al.  Synthetic lethality between CCNE1 amplification and loss of BRCA1 , 2013, Proceedings of the National Academy of Sciences.

[30]  Roger J. Davis,et al.  TNF and MAP kinase signalling pathways. , 2014, Seminars in immunology.

[31]  Gary D Bader,et al.  The Genetic Landscape of a Cell , 2010, Science.

[32]  Eytan Ruppin,et al.  A Genome-Wide Systematic Analysis Reveals Different and Predictive Proliferation Expression Signatures of Cancerous vs. Non-Cancerous Cells , 2013, PLoS genetics.

[33]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[34]  S. Nijman.  Synthetic lethality: General principles, utility and detection using genetic screens in human cells , 2011, FEBS letters.

[35]  Guy Cavet,et al.  Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers" , 2007, Science.

[36]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[37]  Walter Jonat,et al.  Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment , 2014, Oncology.

[38]  A. Ashworth,et al.  Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.

[39]  Yunyan Gu,et al.  Analysis of pathway mutation profiles highlights collaboration between cancer‐associated superpathways , 2011, Human mutation.

[40]  Hongxia Zhu,et al.  EB1 acts as an oncogene via activating β‐catenin/TCF pathway to promote cellular growth and inhibit apoptosis , 2009, Molecular Carcinogenesis.

[41]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[42]  S. Zimmer,et al.  It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. , 2005, Cancer research.

[43]  Jeremy M. Stark,et al.  53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.

[44]  S. Fulda,et al.  Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. , 2014, Oncogene.